8,081 trials (keyword fallback)
Alzheimers Disease · Postoperative Delirium · Post Operative Cognitive Dysfunction
Primary: Correlation Between Perioperative Change in Cerebrospinal Fluid (CSF) Markers of Alzheimers Disease and Perioperative Cognitive Change — -1.21; -5.09; -0.44 pg/ml
Dementia · Family Caregiver
Primary: Change From Baseline in Burden on the German Version of Zarit Caregiver Burden Interview (ZBI) (5-point Scale) at Month 6 — -0.43; 7.05 units on a scale — p=<0.001
Alzheimer Disease · Neurodegenerative Diseases
Primary: Alpha-synuclein Levels From Nasal Swabs
Alzheimer Disease
Primary: Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment. — 0.35; 0.20; 0.26; 0.32 z-score — p=0.3236
Alzheimer Disease
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 5; 3; 6; 3 participants
Amyloid Beta Protein
Primary: Amyloid Beta Levels in CSF — -12.7; 6.74; -22.73; -25.63 pg/mL
Dementia
Primary: Rate of Change of Hippocampal Volume Slope — -70.2418748; -88.4738591; -94.0768115; -46.9484805 mm^3/year — p=0.095
Alzheimer Disease
Primary: Generalized Anxiety Disorder-7 (GAD-7) Anxiety Score — -0.014; -0.008; -0.005; -0.013 score on a scale change per day — p=0.247
Chronic Kidney Disease
Primary: Whole Blood Platelet Aggregation to 0.5 Millimoles Arachidonic Acid — 21.0; 18.0; 0; 0 ohms
Scleroderma
Primary: Improvement in the Modified Rodnan Skin Score. — 46.75 percent improvement from baseline
Chagas Disease
Primary: Part 1 - Percentage of Sero-reduction or Sero-conversion (Cured Subjects) — 32.9; 18.9 Percentage of subjects
Rheumatoid Arthritis
Primary: Mean 48-week Change in DAS28 — -2.12; -2.29 units on a scale
Gaucher Disease
Primary: Number of Severe Adverse Events (SAE) — 1 events
Alopecia Areata
Primary: Change in SALT Score — 65.8; 24.8; 7.3 score on a scale
Multiple Sclerosis
Primary: Number of Patients With a Return of Disease Activity After the Third Month Post-first-infusion — 3; 6 Participants